Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cabaletta Bio, Inc. (CABA)

Cabaletta Bio Q3 net loss widens to $53.1 million; cash reported at $299.4 million

Mixed Impact 3 of 5 earnings Written later

Cabaletta Bio reported third-quarter 2026 results, with a net loss of $53.1 million, up from $44.9 million a year earlier, though the per-share loss narrowed to $0.28 from $0.44. The company said cash of $299.4 million, including about $115.0 million from warrant exercises, extends its operating runway into the first quarter of 2028.

Key points

  • Q3 2026 net loss was $53.1 million, or $0.28 per share, versus $44.9 million, or $0.44 per share, in Q3 2025.
  • Research and development expenses rose to $47.1 million from $39.8 million; general and administrative expenses rose to $7.6 million from $6.8 million.
  • Cash and cash equivalents were $299.4 million at September 30, 2026, including about $115.0 million from warrant exercises before their September 12, 2026 expiration.
  • RESET-Myositis registrational topline results are expected in the second half of 2027, with a BLA submission planned for the first quarter of 2028.

The filing

CompanyCabaletta Bio, Inc. (CABA)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:31 AM ET
Accession number0001759138-26-000046

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.